Doern G V, Brueggemann A B, Pfaller M A, Jones R N
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
Arch Pathol Lab Med. 1999 Apr;123(4):285-9. doi: 10.5858/1999-123-0285-AOLPWS.
To assess the performance of clinical microbiology laboratories in the United States when conducting in vitro susceptibility tests with Streptococcus pneumoniae.
The results of a nationwide College of American Pathologists Proficiency Survey test sample, in which susceptibility testing of an isolate of S. pneumoniae was performed, were assessed with respect to precision and accuracy.
Wide variability was noted among participating laboratories with both minimum inhibitory concentration procedures and disk diffusion susceptibility tests when both methods were applied to S. pneumoniae. Despite this high degree of variation, categorical interpretive errors were uncommon. Numerous laboratories reported results for antimicrobial agents that are not recommended by the National Committee for Clinical Laboratory Standards for tests with S. pneumoniae.
Current susceptibility testing practices with S. pneumoniae in the United States indicate limited precision and a tendency for laboratories to test and report results obtained with antimicrobial agents of questionable therapeutic value against this organism. Continued efforts to standardize susceptibility testing of S. pneumoniae in the United States are warranted. In addition, modifications of existing interpretive criteria may be necessary.
评估美国临床微生物实验室对肺炎链球菌进行体外药敏试验时的表现。
对美国病理学家协会全国能力验证调查测试样本的结果进行评估,该样本对一株肺炎链球菌进行了药敏试验,评估内容包括精密度和准确性。
当两种方法应用于肺炎链球菌时,参与实验室在最低抑菌浓度程序和纸片扩散药敏试验方面均存在很大差异。尽管差异程度很高,但分类解释错误并不常见。许多实验室报告了美国国家临床实验室标准委员会不推荐用于肺炎链球菌检测的抗菌药物的结果。
美国目前对肺炎链球菌的药敏试验做法表明精密度有限,且实验室倾向于检测和报告使用对该菌治疗价值存疑的抗菌药物所获得的结果。美国有必要继续努力规范肺炎链球菌药敏试验。此外,可能需要修改现有的解释标准。